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Abstract Nanoparticles (NPs) are developed for
many applications in various fields, including nano-
medicine. The NPs used in nanomedicine may disturb
homeostasis in blood. Secondary hemostasis (blood
coagulation) and fibrinolysis are complex physiolog-
ical processes regulated by activators and inhibitors.
An imbalance of this system can either lead to the
development of hemorrhages or thrombosis. No data
are currently available on the impact of NPs on
fibrinolysis. The objectives of this study are (1) to
select a screening test to study ex vivo the impact of
NPs on fibrinolysis and (2) to test NPs with different
physicochemical properties. Euglobulin clot lysis time
test was selected to screen the impact of some NPs on
fibrinolysis using normal pooled plasma. A dose-
dependent decrease in the lysis time was observed
with silicon dioxide and silver NPs without disturbing
the fibrin network. Carbon black, silicon carbide, and
copper oxide did not affect the lysis time at the tested
concentrations.
Keywords Nanoparticles  Fibrinolysis 
Hemocompatibility  Blood  Nanomedicine
Introduction
Nanotechnology is a promising area of growing
scientific developments. The development of novel
nanomaterials (NMs) and their use in biomedicine has
received much attention in recent years. Nanoparticles
(NPs) offer many opportunities for medical devices as
therapeutics, diagnostics, imaging, and drug delivery
(De Jong and Borm 2008; Moghimi et al. 2005).
All these various applications may lead to an
increase of human exposure. Due to the reduced
particle size and increased surface area, NPs can enter
the body and translocate into systemic blood flow after
inhalation, ingestion, dermal contact, or systemic
administration (Oberdorster et al. 2005). Besides this
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risk, information on potential side effects is still
lacking (Ahamed et al. 2010; You et al. 2011, 2012).
Although the question about the potential toxicity of
NPs on human health is considerable and of increasing
concern worldwide, it remains a complex issue with
currently very limited answers.
New therapeutic and diagnostic agents using nan-
otechnologies require being hemocompatible (Dobro-
volskaia et al. 2008a; Simak 2009). Indeed, NPs in close
contact with blood components may impact cells (red
blood cells, platelets, leucocytes,…) or physiological
processes such as complement, coagulation and fibri-
nolysis (Simak 2009). Evaluating the blood compatibil-
ity (or hemocompatibility) of potential nanomedical
products is of primary concern in the context that these
products are intended to be administered through the
bloodstream (Moghimi et al. 2005). Especially, the
evaluationof the thrombogenic potential of aNMaims at
exploring how this material may interact with or affect
functions of these hemostatic system (Simak 2009). In
particular, fibrinolysis is a complex physiological pro-
cess resulting in the degradation of the fibrin scaffold to
avoid thrombosis and to supply oxygen to the surround-
ing tissue (Flemmig andMelzig 2012). The plasmin, the
main enzyme responsible for this degradation, is present
in the plasma in its inactive form called plasminogen.
Fibrinolysis is highly regulated by activators (i.e., tissue
plasminogen activator (t-PA), urokinase-type plasmino-
gen activator (u-PA)) and inhibitors (i.e., plasminogen
activator inhibitor-1 (PAI-1), a2-antiplasmin, thrombin-
activatable fibrinolysis inhibitor (TAFI)) (Collen and
Lijnen 1991). Nanoparticlesmay interactwith activators
and inhibitors at different stages of the fibrinolytic
pathway. A dysregulation of hemostatic balance leads to
a disorder with either thrombotic or hemorrhagic
symptoms prevailing (Boudjeltia et al. 2002). Based on
in vivo adverse effects, thrombogenicity refers to the
trend of amaterial to induce or promote clot or thrombus
formation in thebloodstream, therebypossibly leading to
thrombotic symptoms. Consequently, preclinical evalu-
ation of NMs on the multifaceted blood system is an
essential step to ensure their design as non-toxic agents
with optimum hemocompatibility (Dobrovolskaia et al.
2008a).
For NPs, no guidelines are currently available for
the evaluation of their hemocompatiblity. Some
studies report the hemocompatibility of NPs, in
particular on red blood cells, platelets, and coagulation
process (Dobrovolskaia et al. 2008b; Krajewski et al.
2013; Laloy et al. 2012, 2014a; Mocan 2013). More
specifically, our team assessed and validated some
specific techniques for the study of NPs on red blood
cell hemolysis, primary hemostasis (platelet adhesion,
activation, and aggregation), and secondary hemosta-
sis (blood coagulation) (Laloy et al. 2012, 2014a, b).
No data are currently available on the impact of NPs
on fibrinolysis. The primary objective of this study is
to select an ex vivo test to study the impact of NPs on
fibrinolysis, available as a preclinical screening assay.
NPs with different physicochemical properties were
then tested on the most appropriate selected assay.
Methods
Nanoparticles characterization
Carbon black (CB, Printex, 21 nm) and silicon dioxide
(SiO2, 15 nm), silicon carbide (SiC, 60 nm), and
copper oxide (CuO) were obtained, respectively, from
Evonik Degussa Corporation (USA), Sigma-Aldrich
(USA), and Io-Li-Tec (Germany) as nanopowders.
Silver NPs were obtained from partner of the European
project NanoValid. They were suspended in water at a
stock concentration of 40 mg/mL, stabilized by
polyvinyl pyrolidone (PVP), and stored at 4 C. No
trace of endotoxin was found in these NMs using the
endotoxin Limulus Amebocyte Lysate kit (Lonza,
Switzerland).
The nanopowders were suspended in Tyrode buffer
[10 mM Hepes, 6 mM NaHCO3, 137 mM NaCl,
2.7 mM KCl, 5 mM glucose, 1 mM MgCl2, and
0.8 mM NaH2PO4, diluted in ultrapure water (milliQ
18.2 MW.cm), pH 7.4]. Tyrode buffer was also used
for the dilution of Ag NPs suspension. The NPs stock
suspensions were prepared at a concentration of 1 mg/
mL for the characterization of NPs in suspension, at
10 mg/mL for the fibrinolysis experiments and were
stirred for 30 min.
The physicochemical characterization of the
nanopowders was previously reported (Laloy et al.
2012). The average diameter measured by FEG-SEM/
TEM, the specific surface area by BET, the bulk
composition by EDX, and the surface composition by
XPS are presented in Table 1. These experimental
data were compared with the information supplied by
the manufacturers. The results were generally in
agreement with the supplied data. All the studied
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NMs have a spheroid shape except CuO which has a
fiber shape. For CuO, the average length was also
measured (59.1 ± 28.0 nm). Regarding the specific
surface area, discrepancies with manufacturer data
were observed for most of the NPs confirming the need
of a complete physicochemical characterization in
studies. The nanopowder surface composition was not
similar to their bulk composition for most of the NPs
(SiC, CuO and Ag) with a greater content of oxygen in
surface. For Ag, the other elements are attributed to
traces present in the suspension solution.
Preparation of human normal pooled plasma
Normal pooled plasma (NPP) was prepared with blood
from 40 healthy volunteers who were free from any
medication for at least 2 weeks. The exclusion criteria
were thrombotic and/or hemorrhagic events, antipla-
telet and/or anticoagulant medication, pregnancy, and
uptake of drugs potentially affecting the platelet
functions and/or coagulation factor during the 2 weeks
prior to blood draw. A written informed consent was
obtained from each donor. The study population
displayed the following characteristics: 24 females
and 16 males aged from 19 to 48 years (mean
age = 25 years) with body mass index (BMI) ranging
from 16.8 to 34.6 kg/m2 (mean BMI = 22.3 kg/m2).
Blood was collected by venipuncture into tubes
containing buffered sodium citrate (109 mM, nine
parts blood to one part of sodium citrate solution) (BD
Vacutainer). The study protocol was in accordance
with the Declaration of Helsinki and was approved by
the Medical Ethical Committee of the Centre Hospi-
talier Universitaire Dinant-Godinne UCL Namur
(Yvoir, Belgium).
After collection of blood, the platelet-poor plasma
(PPP) was obtained from the supernatant fraction of
the blood tubes after a double centrifugation for
15 min at 1500 g at room temperature. It was imme-
diately frozen at -80 C after centrifugation.
Preparation of human platelet poor plasma
from individual donors
PPP was prepared with blood from seven healthy
volunteers who were free from any medication for at
Table 1 NPs characterization










CB Measured 36.4 ± 1.3 124 86.6 % C 13.4 % O 87.3 % C 12.7 % O
Suppliedc 21 115 NAd NAd
SiO2 Measured 19.9 ± 3.5 68 29.2 % Si 70.8 % O 28.8 % Si 71.2 % O
Suppliedc 10–20 140–180 99.5 %e NAd
Sic Measured 53.4 ± 12.4 30 65.6 % C 7.5 % O 26.9 % Si 71.8 % C 26.4 % O
1.8 % Si
Suppliedc 60 80 99.5 %e NAd
CuO Measured 11.71 ± 4.6/59.1 ± 28.0f 18.4 56.7 % Cu 43.3 % O 49.8 % Cu 50.2 % O
Suppliedc 12 NAd 99.5 %e NAd
Ag Measured 16 (primary particles)
71 (agglomerates)
NFg 4.71 % Ag, 34.22 % O,
60.78 % C, 0.29 % Na
5 % Ag, 23.8 % O,
61 % C, 9.2 % N, 1 % Na
Suppliedc NAd NAd NAd NAd
a Results are expressed as mean ± 1 SD
b Results are expressed as % of atomic element
c Information supplied by the manufacturers
d NA not available
e Product purity
f Average length of fiber particles
g NF not feasible
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least 2 weeks [3 females and 4 males aged from 23 to
51 years (mean age = 28 years)]. The exclusion cri-
teria and the protocol of centrifugation are similar to
the protocol used for NPP.
Euglobulin clot lysis time (ECLT)
It is the most common test used in laboratories to
estimate plasma fibrinolytic capacity (Boudjeltia et al.
2002). This method is applied in clinic to normal
healthy and pathological people. A shortened lysis
time indicates a hyperfibrinolytic state with bleeding
risk and an elongated lysis time indicates trend to
thrombogenicity (Boudjeltia et al. 2002).
0.5 % of acetic acid was added to 500 lL of plasma
in a 19:1 proportion and was incubated at 4 C for
15 min. Fraction containing plasminogen, plasmino-
gen activators [u-PA, t-PA], and fibrinogen is defined
as euglobulin precipitate. The solution is then cen-
trifuged at 25009g for 15 min at 4 C. The super-
natant containing inhibitors of fibrinolysis is
discarded. The pellet is redissolved in 500 lM Na2-
HPO4 0.05 M. Once dissolved, 500 lL of solution is
placed in a cuvette in the machine thermostatized at
37 C. 30 lL of NPs dispersed in tyrode buffer or
tyrode buffer alone (negative control) is added in the
cuvette. 470 lL of euglobulin solution is added. Then,
100 lL of thrombin 20 U/mL [Fibrinogen 5 (STAGO)
diluted fourfold] is added to generate the fibrin
scaffold. The detection is based on spectrophotometric
(890 nm) microtiter plate reader which measures the
optical density changes in euglobulin clot of plasma
over time (Smith et al. 2003). The reference time for
physiological fibrinolysis is between 210 and
540 min. If fibrinolysis occurs between 10 and 30
min, the risk of hemorrhage is high, between 30 and 60
min, the risk is low and between 60 and 120 min, the
risk is limited.
The results were expressed as means ± 1 SEM
(n C 2). Statistical analyses were performed with
GraphPad Prism software using the unpaired t test.
Scanning electron microscopy
50 lL of tyrode buffer (negative control) or SiO2 or Ag
NPs (final concentration: 100 lg/mL) and 100 lL of
CaCl2 (final concentration: 25 mM) are added to 850
lL of NPP. The solution is then incubated in a bath at
37 C. A fibrin clot is formed within 5 min. 500 lL of
2.5 % glutaraldehyde in cacodylate buffer (Na(CH3)2
AsO23H2O in distilled water at pH 7.4, final concen-
tration : 0.1 M) was added and incubated for 90 min.
The glutaraldehyde solution was removed and 400 lL
of 0.2 M cacodylate buffer was added. The next step is
the dehydration of the sample with successive baths of
alcohol from 30 to 100. A critical point drying was
performed with the Balzers Critical Point Dryer (CPD)
030 (BAL-TEC Gmbh, Germany). Then, a thin layer
of platinum (11.6 nm) was deposited under argon
atmosphere on the sample with the metallizer Balzers
union (BAL-TEC Gmbh, Germany). The samples
were observed with FEG-SEM (Jeol, Japan; resolution
of 0.6 nm at 20 keV).
Results
Fibrinolysis assays
Two types of biological laboratory assays to explore
fibrinolysis are available: (1) specific assays exploring
specific agents of the fibrinolysis process; (2) semi-
global fibrinolysis assays studying the semi-global
process of fibrinolysis.
Specific fibrinolysis assays do not provide infor-
mation about the fibrinolysis process but measure the
amount or activity of isolate components of the
fibrinolytic system. Several assays exist: plasminogen,
fibrinogen, alpha-2-antiplasmin (Alpha-2-Plasmin
Inhibitor), plasminogen/antiplasmin, tissue plasmino-
gen activator (t-PA), plasminogen activator inhibitor-
1 (PAI-1), thrombin activatable fibrinolysis inhibitor
(TAFI) (Bertelmann et al. 2013; Meltzer et al. 2010;
Montes et al. 1996; Tait et al. 1992). Another assay,
the D-dimers assay, is useful for clinical application
since it aims at measuring the fibrin D-dimer levels
which is a sign of a recent fibrinolysis and considered
as a clinical marker of thrombogenesis (Mullier et al.
2013; Schouten et al. 2013). These specific assays,
based on enzyme-linked immunosorbent assays, can-
not be applied ex vivo to study the impact of NPs on
the fibrinolysis process without resorting to animal
experiments. Consequently, we recommend to use
semi-global fibrinolysis assay to screen the impact of
NMs on the fibrinolysis process.
Among semi-global fibrinolysis assays, thromboe-
lastometry is a viscoelastic whole-blood assay evalu-
ating the hemostatic capacity of blood (Wikkelsoe
317 Page 4 of 9 J Nanopart Res (2015) 17:317
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et al. 2011). The advantage of this technique is the use
of whole blood which is closer to reality than assays
performed in plasma. Thromboelastometry is a suit-
able technique for detection of highly pathological
hyperfibrinolysis to evaluate the guide transfusion
therapy for diagnosis and goal-directed therapy of
perioperative massive hemorrhage (Lier et al. 2013).
However, its limited running time of 8 h does not
allow applying this technique as a screening assay to
evaluate the potential of NMs to disbalance the
fibrinolytic process. Indeed, its limited running time
of 8 h affords only to detect highly pathological
hyperfibrinolysis with no reference to negative
control.
Euglobulin clot lysis time (ECLT) is an assay
measuring the time required for clot dissolution.
Plasma fibrinolytic activity has been assessed by
ECLT since late 1950s. The detection is based on
spectrophotometric (890 nm) microtiter plate reader
which measures the optical density changes in
euglobulin clot of plasma over time (Smith et al.
2003).
The ECLT assay was first performed in duplicates
with the blood of seven different healthy donors and
NPP from 40 healthy volunteers at seven different
times. Values of lysis time from healthy donors
showed a high inter-individual variability with a
minimum value of 63.20 min, a maximum value of
692.1 min, and a coefficient of variation of 89.39 %
(Fig. 1). With NPP, we observed a minimum value of
385.3 min, a maximum value of 628.2 min, and a
coefficient of variation of 14.68 % (Fig. 1). The data
from the individual donors were separated into two
groups: 4 individual donors had a lysis time\200 min
(3 females aged 23–24 years and 1 male aged
51 years) and 3 individual donors had a lysis time[
400 min (3 males aged 24–26 years). Consequently,
to avoid high inter-donor variability, we decided to
perform our experiments using only NPP.
To avoid the inter-experiment negative control
value fluctuation, we decided to express the result as
absolute value (average of the lysis time of the sample/
average of the lysis time of the negative control).
Five different NPs were tested on ECLT using NPP
at three final concentrations (1, 10, and 100 lg/mL).
SiC and CBNPs had no impact on the fibrinolysis time
at the tested concentrations (Fig. 2). CuO NPs demon-
strated a dose-dependent decrease in lysis time
although not statistically significant. SiO2 and Ag
NPs were profibrinolytic. Ag NPs induced a significant
decrease of the lysis time at 10 lg/mL. At 100 lg/mL,
SiO2 NPs and Ag NPs induced a 1.2-fold and 1.5-fold
decrease, respectively, but raw values remained in the
physiological range (mean = 377.68 min for SiO2
NPs and 351.57 min for Ag NPs).
Scanning electron microscopy (SEM) was used as a
qualitative technique to study the fibrin fiber mor-
phology as already done in the literature (Swanepoel
et al. 2014). Because of a profibrinolytic potential of
SiO2 NPs and Ag NPs on the ECLT assay, we decided
to investigate if ultrastructural changes occurred in the
presence of these NPs compared to our control,
potentially inducing a loose fibrin network explaining
the shortened lysis time. SEMmicrographs showed no
structural change in the fibrin scaffold in the presence
of SiO2 or Ag NPs compared to the control (Fig. 3). In
Fig. 3e, a white arrow shows an SiO2 NPs agglomerate
(maximal length: 5.8 lm and minimal width: 2.5 lm).
Discussion
In this work, we evaluated the ECLT to study ex vivo
the impact on fibrinolysis of manufactured NMs. This
is the first scientific paper assessing methods to study
the impact of NMs on fibrinolysis. Five NPs (SiO2,
SiC, CB, CuO, and Ag) with different physicochem-
ical profiles, most of them currently developed in
nanomedicine were tested (Chen et al. 2013; de Mel
et al. 2012; Pelgrift and Friedman 2013). Their
Fig. 1 Lysis time of seven different individual donors and lysis
time of NPP from 40 healthy volunteers performed at seven
different times (n = 2)
J Nanopart Res (2015) 17:317 Page 5 of 9 317
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physicochemical properties were widely characterized
and their potential pro- or anti-fibrinolytic activity was
evaluated with the selected assay, the ECLT.
We identified ECLT as the most suitable assay to
assess the impact of NPs on fibrinolysis. A spec-
trophotometric (890 nm) microtiter plate reader mea-
sures the optical density changes in euglobulin clot of
plasma over time. It is known that NPs interfere with
methods using light absorbance detection (Laloy et al.
2012). Although ECLT is based on an optical density,
there is no light interference with this assay. Indeed,
the informatics system records the absorbance over
time, and the time at which there is sudden decrease in
absorbance due to clot lysis is recorded which
corresponds to the lysis time. Interestingly, even if
the tested NPs absorb at the wavelength, they do not
mask the detection point, i.e., the change of absor-
bance at the lysis time. This assay suffers from some
limitations that need to be taken into consideration.
Because of specific precipitation of euglobulins, it
does not measure ‘‘natural’’ fibrinolysis. In fact, during
the sample preparation, a part of activators and the
majority of inhibitors of fibrinolysis are removed.
Because of redissolution of the euglobulin clot in
Na2HPO4 in the protocol, interactions between NPs
and other blood components (RBC, WBC…) or
plasma proteins are not taken into account. The
potential corona effect induced by plasmatic protein
coating on NPs may therefore be underestimated
(Dobrovolskaia et al. 2014). Still, ECLT is the most
suitable assay to evaluate ex vivo the impact of NPs on
fibrinolysis especially for a screening study.
Fibrinolysis time depends on many variables such
as the circadian rhythm, the stress, the venous
stasis, the weight… (Laffan and Manning 2006)
High inter-individual variabilities in the lysis time
were demonstrated with the plasma of seven healthy
donors during the pre-test. To avoid this high
variability, we decided to work with NPP of 40
healthy donors.
No change in the lysis time was observed with SiC
and CB NPs. CuO NPs suggested a dose-dependent
decrease in the lysis time although not statistically
significant. SiO2 and Ag NPs showed a decrease in the
lysis time. However, this decrease in the population of
40 healthy donors was not pathological because raw
values of lysis time with SiO2 and Ag NPs were in
the reference range for physiological fibrinolysis
Fig. 2 Impact of different concentrations of NPs reported to negative control in absolute values. The results were expressed as
means ± 1 SEM (n C 3). Statistical analyses were performed with GraphPad Prism software using the unpaired t test
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(between 210 and 540 min). We used SEM as a
qualitative technique to study the impact on the fibrin
network of NPs showing profibrinolytic potential with
ECLT assay, i.e., SiO2 and Ag NPs. SEMmicrographs
revealed no ultrastructural changes in the structure
scaffold in the presence of SiO2 or Ag NPs compared
to the control. Consequently, these NPs did not
prevent the formation of a solid fibrin scaffold as
observed with the control. As demonstrated in previ-
ous studies, SiO2 and Ag NPs are also procoagulants
(Laloy et al. 2012, 2014a). One potential hypothesis of
the underlying mechanism is that the charges of SiO2
and Ag NPs induce a catalytic surface for coagulation
and fibrinolytic factors, disturbing the hemostatic
balance.
We observed an agglomerate of SiO2 NPs in plasma
on SEM micrographs with a length of 5.8 lm. The
diameter range of capillaries is between 5 and 7 lm
(Pries and Secomb 2003). Consequently, there is a
concern about NP agglomerates getting trapped
in capillary narrowings and disturbing capillary
exchanges. The concentration of NPs in the blood
stream influences the degree of agglomeration leading
to modification of specific surface area that may have
an impact on the toxicity. Inherent properties of NPs
developed for nanomedicine, such as size and
agglomeration potential, should be evaluated to ensure
their design as non-toxic agents in the blood stream
(Hock et al. 2011).
To promote safe and ethical development of new
pharmaceuticals, we support that the nanodrugs have
to be subjected to multifaceted blood system testing in
early preclinical development prior to animal or
human exposure. Indeed, ex vivo nonclinical hemo-
compatiblity safety studies characterize potential toxic
effects and the information provided is helpful in
guiding the selection of an initial maximum safe dose.
Conclusion
The development of reliable non clinical assays is
essential to assess the hemocompatibility of NMs and
to ensure their design as non-toxic agents with
Fig. 3 SEMmicrographs: control fibrin clot (a, d), fibrin clot in the presence of SiO2 NPs 100 lg/mL (b, e) and in the presence of Ag
NPs 100 lg/mL (c, f). Scale bar = 10 lm (a–c); 1 lm (d–f). White arrow: SiO2 agglomerate
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optimum hemocompatibility (Dobrovolskaia et al.
2008b). This is the first scientific paper assessing
several methods to explore the impact of NMs on
fibrinolysis. Among the existing assays, the ECLT
assay was found suitable. Using this method, SiO2 and
Ag NPs showed an impact on fibrinolysis at high
concentrations. Taken together with our previous
studies on hemolysis, primary hemostasis, and sec-
ondary hemostasis, this study provides the scientific
knowledge for an international guidance/guideline
document on hemocompatibility of NMs.
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